917358-65-7 Usage
Uses
Used in Pharmaceutical Industry:
N-Methylpiperazine--d8 is used as a key intermediate in the preparation of 2-(4-Methyl-1-piperazinylmethyl)acrylophenone (MPMAP), an antimicrotubular drug. It aids in the development of this drug, which has potential applications in treating various diseases by disrupting microtubule dynamics in cells.
Used in COVID-19 Research:
N-Methylpiperazine--d8 is used as a COVID-19-related research product, contributing to the ongoing efforts to understand and combat the virus. Its involvement in research may lead to the discovery of new treatments or therapeutic approaches against COVID-19.
Used in Inflammatory Disorders Treatment:
N-Methylpiperazine--d8 is used in the preparation of Imidazopyridine compounds, which have potential applications in the treatment of inflammatory disorders. These compounds may help in managing inflammation and related symptoms by targeting specific pathways involved in the inflammatory response.
Check Digit Verification of cas no
The CAS Registry Mumber 917358-65-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,7,3,5 and 8 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 917358-65:
(8*9)+(7*1)+(6*7)+(5*3)+(4*5)+(3*8)+(2*6)+(1*5)=197
197 % 10 = 7
So 917358-65-7 is a valid CAS Registry Number.
917358-65-7Relevant articles and documents
DEUTERIUM-MODIFIED BRIGATINIB DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF
-
Paragraph 0180; 0183, (2018/10/15)
The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.
KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 0319; 0326; 0451; 0454, (2016/09/26)
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.